Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma.
Patients with locally advanced cervical cancer have a poor prognosis. The efficacy of radiotherapy is limited by the presence of large tumor volume and nodal disease. As cisplatin is a documented radiosensitizer and has activity in squamous cell carcinomas, a prospective study was designed to evaluate the toxicity and potential synergism of concurrent cisplatin (20 mg/m2 x 5 d every 21 days) and radiotherapy in locally advanced cervical cancer. Forty-three patients were studied, of which 14 were stage IB/IIA (bulky disease) and 29 were stage IIB/IIIB/IVA. Of the 32 evaluable patients, there were 29 complete responders. Of these 29 patients, 27 remain without evidence of disease, with a median follow-up of 12 months. There were no treatment-related deaths. Cisplatin and radiotherapy appear to be a well-tolerated and highly effective regimen for locally advanced cervical cancer.
Department of Obstetrics and Gynecology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10461.
C D
CD
Runowicz
S
S
Wadler
L
L
Rodriguez-Rodriguez
P
P
Litwin
M
M
Shaves
K A
KA
O'Hanlan
G L
GL
Goldberg
C T
CT
Tomaino
R
R
Byrnes
D000328:Adult; D000368:Aged; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects / Q000528:radiation effects; D008875:Middle Aged; D009367:Neoplasm Staging; D010976:Platelet Count / Q000187:drug effects / Q000528:radiation effects; D011379:Prognosis; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D014057:Tomography, X-Ray Computed; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*
D015295:Antigens, Tumor-Associated, Carbohydrate; D002945:Cisplatin